Liquid Biopsy by Next-Generation Sequencing: a Multimodality Test for Management of Cancer

Achi, Hanadi El; Khoury, Joseph D.; Loghavi, Sanam

doi:10.1007/s11899-019-00532-w

Cited by 14 publications

(6 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Growing evidence supports the utility of ctDNA analysis as a "liquid biopsy" technology to diagnose and monitor cancer disease status (21)(22)(23). With the development of more sensitive ctDNA assay technologies such as Cancer Personalized Profiling by Deep Sequencing (CAPP-seq) (24), mutations of low allelic frequency (e.g., <0.5%) can now be reliably detected (25,26).…”

Section: Discussionmentioning

confidence: 99%

Inhibition of IL1β by Canakinumab May Be Effective against Diverse Molecular Subtypes of Lung Cancer: An Exploratory Analysis of the CANTOS Trial

et al. 2020

View full text Add to dashboard Cite

is employee and owns stocks in Novartis. In addition, C. Wong has a patent IL-1b antibodies for the treatment of cancer pending. J. Baum, M.T. Beste, A. Silvestro, B. Bharani-Dharan and S. Xu are employees and owns stocks in Novartis. Y. A. Wang was previous employee and owns stocks in Novartis. X. Wang reports personal fees outside the submitted work. M.F. Prescott, and L. Krajkovich are employees and owns stocks in Novartis. M. Dugan was previous employee and owns stocks in Novartis. In addition, M. Dugan has a patent IL-1b antibodies for the treatment of cancer pending. P.M Ridker reports grants and personal fees from Novartis (research grant and consultant). AM. Martin is employee and owns stocks in Novartis. E. C. Svensson is employee and owns stocks in Novartis.

show abstract

Section: Discussionmentioning

confidence: 99%

Inhibition of IL1β by Canakinumab May Be Effective against Diverse Molecular Subtypes of Lung Cancer: An Exploratory Analysis of the CANTOS Trial

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The current reported limit of detection by different ctDNA-targeted NGS platforms ranged from 0.004 to 2% [107]. However, the reproducibility and accuracy of alterations detected at low VAF have been variable across different platforms [39,106].…”

Section: Technical Limitations Leading To False Positive and Negative...mentioning

confidence: 99%

Circulating Tumor DNA-Based Genomic Profiling Assays in Adult Solid Tumors for Precision Oncology: Recent Advancements and Future Challenges

Chan

Chin

Low

2022

Cancers

View full text Add to dashboard Cite

Genomic profiling using tumor biopsies remains the standard approach for the selection of approved molecular targeted therapies. However, this is often limited by its invasiveness, feasibility, and poor sample quality. Liquid biopsies provide a less invasive approach while capturing a contemporaneous and comprehensive tumor genomic profile. Recent advancements in the detection of circulating tumor DNA (ctDNA) from plasma samples at satisfactory sensitivity, specificity, and detection concordance to tumor tissues have facilitated the approval of ctDNA-based genomic profiling to be integrated into regular clinical practice. The recent approval of both single-gene and multigene assays to detect genetic biomarkers from plasma cell-free DNA (cfDNA) as companion diagnostic tools for molecular targeted therapies has transformed the therapeutic decision-making procedure for advanced solid tumors. Despite the increasing use of cfDNA-based molecular profiling, there is an ongoing debate about a ‘plasma first’ or ‘tissue first’ approach toward genomic testing for advanced solid malignancies. Both approaches present possible advantages and disadvantages, and these factors should be carefully considered to personalize and select the most appropriate genomic assay. This review focuses on the recent advancements of cfDNA-based genomic profiling assays in advanced solid tumors while highlighting the major challenges that should be tackled to formulate evidence-based guidelines in recommending the ‘right assay for the right patient at the right time’.

show abstract

“…The application prospects of the CRISPR-Cas system in gene editing and its clinical application results are increasing rapidly. Further understanding the use of CRISPR-Cas in lung cancer will provide potential solutions for patients with "hard-to-treat" lung cancer and those with acquired drug resistance [109]. Additionally, significant advances in CRISPR-Cas screening methodologies, next-generation sequencing, and liquid biopsies will certainly provide the needed acceleration in understanding tumor evolution and heterogeneity.…”

Section: Prospectmentioning

confidence: 99%

Nano-immunotherapy for lung cancer

Lu¹,

Zeng²,

Zhang³

et al. 2023

Nano TransMed

View full text Add to dashboard Cite

Lung cancer has the highest incidence and mortality rate worldwide. Immunotherapy is a universal treatment for lung cancer, but its overall treatment remains a challenge. Tumor immunoediting is a process in which the immune system restricts or promotes tumor development through elimination, equilibrium, and escape to change tumor immunogenicity and obtain an immunosuppressive mechanism to promote disease progression. An increasing number of immunotherapy drugs, including monoclonal antibody-targeting drugs and chimeric antigen (Ag) receptor-modified T cells (CAR-T cells), have been used in clinical therapy. Additionally, cancer vaccine development and new clustered regularly spaced short palindromes (CRISPR)based combination therapies against cancer open up new avenues for immunotherapy. However, these immunotherapies cause autoimmune induction and non-specific inflammation, with many limitations. The development and study of nanoparticle systems have shown the possibility of localization, pharmacokinetic programming, and immunomodulator co-delivery. Rapid advances in nanotechnology over the past decade have provided a strategic impetus for cancer immunotherapy improvements. Nanotechnology advancements in various aspects, such as virus-like size, high surface-volume ratio, and surface modifications to precisely target specific cell types, can be investigated through cancer vaccine and immunomodulator delivery system development. This review presents the current immunotherapy approaches for lung cancer and emphasizes the current process and prospects of the fusion of cancer immunotherapy, nanotechnology, bioengineering, and drug delivery.

show abstract

Liquid Biopsy by Next-Generation Sequencing: a Multimodality Test for Management of Cancer

Cited by 14 publications

References 83 publications

Inhibition of IL1β by Canakinumab May Be Effective against Diverse Molecular Subtypes of Lung Cancer: An Exploratory Analysis of the CANTOS Trial

Inhibition of IL1β by Canakinumab May Be Effective against Diverse Molecular Subtypes of Lung Cancer: An Exploratory Analysis of the CANTOS Trial

Circulating Tumor DNA-Based Genomic Profiling Assays in Adult Solid Tumors for Precision Oncology: Recent Advancements and Future Challenges

Nano-immunotherapy for lung cancer

Contact Info

Product

Resources

About